Qi F - Search Results

1

Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.

Wei YC, Qi F, Zheng BM, Zhang CG, Xie Y, Chen B, Liu WX, Liu WP, Fang H, Qi SN, Zhang D, Chai Y, Li YX, Wang WH, Song YQ, Zhu J, Dong M. Wei YC, et al. Among authors: qi f, qi sn. Int J Cancer. 2023 Nov 1;153(9):1643-1657. doi: 10.1002/ijc.34672. Epub 2023 Aug 4. Int J Cancer. 2023. PMID: 37539660

2

Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.

Qi F, Dong M, He X, Li Y, Wang W, Liu P, Yang J, Gui L, Zhang C, Yang S, Zhou S, Shi Y. Qi F, et al. Ann Hematol. 2017 Feb;96(2):245-251. doi: 10.1007/s00277-016-2877-6. Epub 2016 Nov 17. Ann Hematol. 2017. PMID: 27858107

3

Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.

Qi F, Wang WH, He XH, Chen B, Gui L, Fang H, Liu P, Wang SL, Yang JL, Song YW, Yang S, Qi SN, Zhou SY, Li YX, Dong M. Qi F, et al. Among authors: qi sn. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):61-70. doi: 10.1016/j.ijrobp.2018.05.046. Epub 2018 May 29. Int J Radiat Oncol Biol Phys. 2018. PMID: 30102205 Clinical Trial.

4

Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.

Qi F, Chen B, Wang J, Lin X, Qi S, Yang J, Zhou S, Wang S, Gui L, Fang H, Liu P, Song Y, Yang S, Li Y, Dong M. Qi F, et al. Among authors: qi s. Leuk Lymphoma. 2019 Nov;60(11):2679-2688. doi: 10.1080/10428194.2019.1599111. Epub 2019 Jul 12. Leuk Lymphoma. 2019. PMID: 31298062

5

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China.

Qi F, Hu X, Liu Y, Wang Z, Duan J, Wang J, Dong M. Qi F, et al. Chin J Cancer Res. 2019 Oct;31(5):749-758. doi: 10.21147/j.issn.1000-9604.2019.05.05. Chin J Cancer Res. 2019. PMID: 31814679 Free PMC article.

6

Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma.

Chai Y, Qi F, Chen B, Gui L, Yang J, Qi S, Song Y, Li Y, Wei Y, Dong M. Chai Y, et al. Among authors: qi f, qi s. Ann Hematol. 2020 Jun;99(6):1303-1309. doi: 10.1007/s00277-020-04035-0. Epub 2020 Apr 24. Ann Hematol. 2020. PMID: 32333152

7

Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring.

Qi F, Cao Z, Chen B, Chai Y, Lin J, Ye J, Wei Y, Liu H, Han-Zhang H, Mao X, Feng X, Dong M. Qi F, et al. Blood Adv. 2021 Jun 8;5(11):2505-2514. doi: 10.1182/bloodadvances.2020001637. Blood Adv. 2021. PMID: 34047776 Free PMC article.

8

Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis.

Chai Y, Liu M, Li Z, Chen Y, Qi F, Li Q, Xu B. Chai Y, et al. Among authors: qi f. Breast. 2022 Apr;62:93-102. doi: 10.1016/j.breast.2022.01.013. Epub 2022 Jan 29. Breast. 2022. PMID: 35134665 Free PMC article. Review.

9

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.

Yu H, Mi L, Qi F, Wang X, Ye Y, Li M, Wang D, Ding N, Wang X, Song Y, Zhu J, Xie Y. Yu H, et al. Among authors: qi f. Aging (Albany NY). 2022 Apr 10;14(7):3203-3215. doi: 10.18632/aging.204008. Epub 2022 Apr 10. Aging (Albany NY). 2022. PMID: 35400665 Free PMC article.

10

First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China.

Chai Y, Chen B, Qi F, Fang H, Qi SN, Guo RY, Li N, Yang Y, Wang SL, Song YW, Yang JL, Zhang D, Wei YC, Li YX, Dong M. Chai Y, et al. Among authors: qi f, qi sn. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):833-844. doi: 10.1016/j.ijrobp.2022.04.001. Epub 2022 Apr 20. Int J Radiat Oncol Biol Phys. 2022. PMID: 35452752 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,045 results

Search Page